According to BioCryst Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.33 B. In 2022 the company made a revenue of $0.27 B an increase over the years 2021 revenue that were of $0.15 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.33 B | 22.37% |
2022 | $0.27 B | 72.31% |
2021 | $0.15 B | 782.38% |
2020 | $17.81 M | -63.53% |
2019 | $48.83 M | 136.45% |
2018 | $20.65 M | -18% |
2017 | $25.18 M | -4.43% |
2016 | $26.35 M | -45.39% |
2015 | $48.25 M | 254.62% |
2014 | $13.6 M | -21.48% |
2013 | $17.33 M | -34.09% |
2012 | $26.29 M | 33.85% |
2011 | $19.64 M | -68.51% |
2010 | $62.38 M | -16.37% |
2009 | $74.58 M | 31.87% |
2008 | $56.56 M | -20.6% |
2007 | $71.23 M | 1046.98% |
2006 | $6.21 M | 3989.72% |
2005 | $0.15 M | 1606.18% |
2004 | $0 M | -99.46% |
2003 | $1.63 M | -7.92% |
2002 | $1.77 M | -84.1% |
2001 | $11.15 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $27.11 B | 8,081.66% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $37.84 B | 11,320.54% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | $1.24 B | 275.16% | ๐บ๐ธ USA |
Repligen
RGEN | $0.63 B | 92.74% | ๐บ๐ธ USA |
Novavax NVAX | $0.69 B | 109.24% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $6.88 M | -97.92% | ๐บ๐ธ USA |
NanoViricides NNVC | N/A | N/A | ๐บ๐ธ USA |
Cel-Sci
CVM | N/A | N/A | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $1.02 B | 208.92% | ๐บ๐ธ USA |